Filing Flows › Halozyme Therapeutics (HALO) › Product sales, net revenue
Halozyme Therapeutics (HALO) Product sales, net revenue by quarter
Halozyme Therapeutics' Product sales, net revenue was $137M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 6 quarters it ranged from $78.0M (Q1 2025) to $137M (Q3 2026).
| Quarter | Product sales, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $137M | +6% | +46% |
| Q2 2026 | $130M | -0.6% | +59% |
| Q1 2026 | $130M | +38% | +67% |
| Q3 2025 | $94.2M | +16% | — |
| Q2 2025 | $81.5M | +4% | — |
| Q1 2025 | $78.0M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' Product sales, net revenue?
Halozyme Therapeutics' Product sales, net revenue was $137M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has Halozyme Therapeutics' Product sales, net revenue changed?
Over the last 6 quarters it ranged from $78.0M (Q1 2025) to $137M (Q3 2026).